This company has been acquired
Landos Biopharma Future Growth
Future criteria checks 0/6
Landos Biopharma's earnings are forecast to decline at 37.1% per annum. EPS is expected to grow by 37.6% per annum.
Key information
-37.1%
Earnings growth rate
37.6%
EPS growth rate
| Pharmaceuticals earnings growth | 17.4% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 24 May 2024 |
Recent future growth updates
Recent updates
Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?
Mar 22
Landos Biopharma appoints Fabio Cataldi as Chief Medical Officer
Sep 06Companies Like Landos Biopharma (NASDAQ:LABP) Could Be Quite Risky
Aug 19Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?
May 05Landos Biopharma (NASDAQ:LABP) Is In A Strong Position To Grow Its Business
Nov 17Landos Biopharma posts positive outcome from omilancor End-of-Phase 2 FDA meeting
Jun 14Landos Biopharma (LABP) Investor Presentation - Slideshow
Jun 08We Think Landos Biopharma (NASDAQ:LABP) Needs To Drive Business Growth Carefully
May 04Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | N/A | -45 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -26 | N/A | N/A | 1 |
| 3/31/2024 | N/A | -25 | -21 | -21 | N/A |
| 12/31/2023 | N/A | -22 | -20 | -20 | N/A |
| 9/30/2023 | N/A | -21 | -19 | -19 | N/A |
| 6/30/2023 | N/A | -23 | -25 | -25 | N/A |
| 3/31/2023 | N/A | -30 | -37 | -37 | N/A |
| 12/31/2022 | N/A | -39 | -46 | -46 | N/A |
| 9/30/2022 | N/A | -54 | -54 | -54 | N/A |
| 6/30/2022 | N/A | -59 | -59 | -58 | N/A |
| 3/31/2022 | 18 | -43 | -31 | -31 | N/A |
| 12/31/2021 | 18 | -38 | -28 | -27 | N/A |
| 9/30/2021 | 18 | -30 | -24 | -23 | N/A |
| 6/30/2021 | 18 | -25 | -17 | -17 | N/A |
| 3/31/2021 | N/A | -34 | -32 | -32 | N/A |
| 12/31/2020 | N/A | -30 | -23 | -23 | N/A |
| 9/30/2020 | N/A | -22 | -17 | -17 | N/A |
| 6/30/2020 | N/A | -17 | -16 | -16 | N/A |
| 3/31/2020 | N/A | -16 | -12 | -12 | N/A |
| 12/31/2019 | N/A | -13 | -10 | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LABP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LABP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LABP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if LABP's revenue is forecast to grow faster than the US market.
High Growth Revenue: LABP is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LABP's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/26 21:08 |
| End of Day Share Price | 2024/05/24 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Landos Biopharma, Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robin Garner Kalley | Craig-Hallum Capital Group LLC |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Christopher Howerton | Jefferies LLC |